AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11288947
Drug: New pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pharmacologic agent (specific agent not mentioned)
Trial: 3358924
Drug: Meat protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat protein (60 g)
Trial: 28511917
Drug: Oral hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypertonic saline (Ior)
Trial: 28511917
Drug: Intravenous hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hypertonic saline (Iiv)
Trial: 28511917
Drug: Oral hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypertonic saline (IIor)
Trial: 28511917
Drug: Intravenous hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hypertonic saline (IIiv)
Trial: 23650412
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with concurrent trastuzumab (arm C)
Trial: 23650412
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with sequential trastuzumab (arm B)
Trial: 25605861
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (arm A)
Trial: 27363518
Drug: Fatty fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty fish (750 g/week)
Trial: 27363518
Drug: Lean fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean fish (750 g/week)
Trial: 26630617
Drug: 0.1% hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% hyaluronate ophthalmic solution
Trial: 21977856
Drug: Liandou Qingmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liandou Qingmai Recipe (treatment group, n = 45)
Trial: 21977856
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group, n = 56)
Trial: 20209464
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g GPLC
Trial: 20209464
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g GPLC
Trial: 16549460
Drug: Cinnamon supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplementation (1.5 g/d)
Trial: 15327724
Drug: Cognitive linguistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive linguistic treatment
Trial: 12949287
Drug: Northstar Iontophoretic
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Northstar Iontophoretic Drug Delivery System (IDDS) with lidocaine (100 mg of 10%) and epinephrine (1.05 mg of 1:10,000)
Trial: 10950829
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 7.5% dextrose in healthy adults
Trial: 10950829
Drug: Insulin deficiency
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin deficiency in young adults with IDDM
Trial: 1550697
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated 500 mg 5-ASA tablets administered after standard meals
Trial: 1550697
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated 500 mg 5-ASA tablets administered 1 h before meals
Trial: 3862607
Drug: 0.6 g
RxNorm normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g oral N‐acetylcysteine/day for 60 days
Trial: 31919558
Drug: Oral iron(II)
RxNorm normalized name: iron(II) sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron(II)
Trial: 16836708
Drug: Cocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (40 mg)
Trial: 23958375
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg/day)
Trial: 23958375
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) chemotherapy
Trial: 11696046
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen immunotherapy (IT)
Trial: 11696046
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (PL)
Trial: 9385883
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for acute myocardial infarction in patients with diabetes
Trial: 9385883
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for acute myocardial infarction in patients without diabetes
Trial: 8201614
Drug: Delayed control
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed control group (no immediate treatment)
Trial: 2510660
Drug: labetalol (L)
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: labetalol (L)
Trial: 3067303
Drug: labetalol (L)
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: labetalol (L) and captopril (C)
Trial: 30926396
Drug: Nasal dilator
RxNorm normalized name: nasal dilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal dilator (placebo) treatment
Trial: 23218699
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravitreal aflibercept (IAI 2Q4)
Trial: 23218699
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravitreal aflibercept (IAI 2Q4 + PRN)
Trial: 21774626
Drug: Open patch
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open patch test with 1% SLS
Trial: 21774626
Drug: Open patch
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open patch test with 1% SLS + PT with 0.5% SLS (SLSPT)
Trial: 21774626
Drug: CONTROL (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONTROL (no treatment)
Trial: 11742432
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg po bid
Trial: 11742432
Drug: Azithromycin 1200
RxNorm normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1200 mg po weekly
Trial: 8237310
Drug: Beveled margins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beveled margins of cavity preparations
Trial: 8237310
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of etched butt-joint cavities with NPG-GMA/ethanol, re-etching, and surface coating with low viscous resin
Trial: 27378556
Drug: Hyaluronan (HY)
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan (HY) injections
Trial: 27378556
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (control) injection
Trial: 11774933
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg tablet dissolved in water)
Trial: 9269706
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg/day fixed dose or titrated up to 40 mg/day)
Trial: 20486463
Drug: Liquor carbonis
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquor carbonis distillate (LCD) solution 15%
Trial: 20486463
Drug: Calcipotriene cream
RxNorm normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene cream 0.005%
Trial: 16061591
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg per day for 1 week)
Trial: 12352275
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day hydroxychloroquine
Trial: 12352275
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment with hydroxychloroquine
Trial: 6367245
Drug: acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol (400 mg/day)
Trial: 6367245
Drug: prazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin (4 mg/day)
Trial: 6367245
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prazosin and acebutolol
Trial: 30481269
Drug: Trivalent, Russian-backbone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent, Russian-backbone, live, attenuated influenza vaccine (LAIV)
Trial: 24118165
Drug: Active magnetic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active magnetic stimulation (25-min sessions, twice a week, 560 mT peak at 10 Hz)
Trial: 23077532
Drug: PCV7 (2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (2-dose group)
Trial: 23077532
Drug: PCV7 (2+1-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (2+1-dose group)
Trial: 19721018
Drug: Mediterranean-style diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean-style diet (<50% of daily calories from carbohydrates) (n = 108)
Trial: 19721018
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet (<30% of daily calories from fat) (n = 107)
Trial: 15224630
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray (BANS) 128 micrograms b.i.d. for 20 weeks
Trial: 11295925
Drug: Immunotherapy (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (combined results)
Trial: 11295925
Drug: Immunotherapy (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (with complete resolution)
Trial: 9508171
Drug: ABVD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD plus low-dose regional (extended-field) radiation therapy (EF RT)
Trial: 3078521
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg daily (n = 200)
Trial: 3078521
Drug: Ranitidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 200 mg daily (n = 200)
Trial: 28298397
Drug: Predictive model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive model using clinical variables (age, BMI, Epworth sleepiness scale, peak troponin levels, use of calcium antagonists)
Trial: 23545907
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, dioic acid)
Trial: 23545907
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (BenzaClin®, clindamycin 1% and benzoyl peroxide 5% gel)
Trial: 20688209
Drug: In-lab 600-mg
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-lab 600-mg clopidogrel loading dose
Trial: 20688209
Drug: Routine 6-h
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine 6-h pre-load with 600-mg clopidogrel
Trial: 16629428
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (neurophysiologically based physiotherapy and aerobic training)
Trial: 1430670
Drug: Imipramine (200-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (200-300 mg daily)
Trial: 4046836
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg/twice daily)
Trial: 31183921
Drug: Eriomin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eriomin 200 mg
Trial: 31183921
Drug: Eriomin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eriomin 400 mg
Trial: 31183921
Drug: Eriomin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eriomin 800 mg
Trial: 30531444
Drug: Isoflavone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone (150 mg dry extract of glycine max) plus probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium bifidum, and Bifidobacterium lactis)
Trial: 30531444
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (1 mg estradiol and 0.5 mg norethisterone acetate)
Trial: 30531444
Drug: Isoflavone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone (150 mg dry extract of glycine max)
Trial: 22765856
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem (2 mL of 2%)
Trial: 22765856
Drug: Topical nitroglycerine
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerine (2 mL of 0.2%)
Trial: 17315409
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg sublingual BUP over one hour (one-day group)
Trial: 17315409
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg sublingual BUP over three days (three-day group)
Trial: 31601585
Drug: Ward-based Goal-Directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ward-based Goal-Directed Fluid Therapy (GDFT)
Trial: 26079842
Drug: Monthly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly home counseling visits by community support agents
Trial: 20852001
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Valsartan + HCTZ (triple combination)
Trial: 20852001
Drug: Valsartan +
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan + HCTZ (dual combination)
Trial: 20852001
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Valsartan (dual combination)
Trial: 20852001
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + HCTZ (dual combination)
Trial: 19828902
Drug: Green plantain-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green plantain-based diet (50 g/L)
Trial: 16731387
Drug: Immediate placement
RxNorm normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate placement of Frialit‐2 Synchro implants (IP) after extraction
Trial: 16731387
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of Frialit‐2 Synchro implants (DP) after a 3‐month healing period
Trial: 16731387
Drug: Both IP
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IP and DP implants
Trial: 8342439
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg of immediate‐release oral morphine tablets
Trial: 3554084
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg X 1 dose of metoclopramide (regimen A)
Trial: 3554084
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg X 2 doses of metoclopramide (regimen B)
Trial: 30203123
Drug: Single escalating
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single escalating doses of RN909 (0.3 to 6 mg/kg SC, or 1 mg/kg IV)
Trial: 30203123
Drug: Multiple escalating
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple escalating doses of RN909 (50 to 150 mg SC)
Trial: 30203123
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of RN909
Trial: 30203123
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of RN909
Trial: 30203123
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple doses of RN909
Trial: 24812901
Drug: Qiju Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiju Dihuang Pill (QDP) for 2-4 weeks
Trial: 24812901
Drug: Qiju Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiju Dihuang Pill (QDP)
Trial: 24829661
Drug: GERD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GERD treatment prior to surgery
Trial: 24829661
Drug: No GERD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GERD treatment prior to surgery
Trial: 21609913
Drug: Manual osteopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual osteopathic therapy
Trial: 28059912
Drug: Phenol injection
RxNorm normalized name: Phenol Injection
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenol injection
Trial: 31638594
Drug: Standard patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard patient education (weekly, basic information)
Trial: 26416253
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement intervention (ONS)
Trial: 18971325
Drug: AVN944 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVN944 (doses ranging from 25 to 250 mg)
Trial: 18971325
Drug: AVN944 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVN944 (doses > 100 mg)
Trial: 18971325
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 doses, one with food and one after fasting)
Trial: 11167281
Drug: 0.1% fluorometholone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluorometholone acetate (steroid group)
Trial: 2842882
Drug: BCAA-enriched solution
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-enriched solution
Trial: 2842882
Drug: Conventional amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional amino acid solution (Control)
Trial: 26685122
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg.kg(‐1) (high dose group)
Trial: 26685122
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg.kg(‐1) (middle dose group)
Trial: 26685122
Drug: Sugammadex 1
RxNorm normalized name: sugammadex 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 1 mg.kg(‐1) (low dose group)
Trial: 25373320
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (1,000 mg iron)
Trial: 16368047
Drug: Transdermal reservoir
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal reservoir system (fentanyl transdermal reservoir)
Trial: 12889679
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg/day
Trial: 10471635
Drug: aerosolized E25
RxNorm normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aerosolized E25 1 mg
Trial: 10471635
Drug: aerosolized E25
RxNorm normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aerosolized E25 10 mg
Trial: 8609344
Drug: L-arginine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (20 g/day for 28 days)
Trial: 8609344
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle syrup in equal amounts)
Trial: 2031820
Drug: aminophylline 2
RxNorm normalized name: aminophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminophylline 2 mg kg‐1
Trial: 2031820
Drug: flumazenil 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flumazenil 0.01 mg kg‐1
Trial: 2031820
Drug: placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo saline 0.1 ml kg‐1
Trial: 29912679
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (IDC)
Trial: 29912679
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (IB)
Trial: 29912679
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (IDC) in extremely low-birthweight infants (<1000 g)
Trial: 29912679
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (IB) in extremely low-birthweight infants (<1000 g)
Trial: 29912679
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (IDC) and Oral ibuprofen (IB)
Trial: 24842181
Drug: Targeted intracluster-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted intracluster-injection (TII) technique
Trial: 24842181
Drug: Double-injection (DI)
RxNorm normalized name: di-isopropylammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection (DI) technique